Publication dates

All regions

Bladder Cancer Industry, October 2014 Market Reports from Top Publishers

You might be interested in: cancer, medical equipment, therapeutics, more »


 
1-20 of about 8 500 reports for Bladder Cancer

Cancer Research UK SWOT Analysis, Strategy, Revenues and Profits

Cancer Research UK SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Diagnosis, detection and prognosis; prevention; and treatment. Cruk provides treatment for various types of cancer such as anal cancer, bladder cancer, bowel cancer, cervical cancer, eye cancer, gastric ...

Tengion, Inc. (Symbol:TNGN) SWOT Analysis, Strategy, Revenues and Profits

Tengion, Inc. (Symbol:TNGN) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... To repair or replace a damaged tissue or organ. Tengion also develops neo-urinary conduit and neo-kidney augment based on its proprietary technology. The company's neo-urinary conduit is used for bladder ...

Pacific Edge Limited (Symbol:PEB) SWOT Analysis, Strategy, Revenues and Profits

Pacific Edge Limited (Symbol:PEB) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... With stage ii or stage iii colorectal cancer. Its cxbladder is a non-invasive laboratory test for the detection of bladder cancer. The company provides diagnostic service through their facilities in new ...

Heat Biologics, Inc. (HTBX) - Financial and Strategic SWOT Analysis Review

Heat Biologics, Inc. (HTBX) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... cancer; hs-310, hs-210 hs-510 are in preclinical stage. Heat biologics product serves various therapeutic areas such as non-small cell lung cancer, hiv infection, parasitic infections and others ...

MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review

MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Pharma adds former vc david urso as senior vice president of corporate development and general counselapr 07, 2014: mei pharma identifies potential biomarker for pracinostat in bladder cancerdec 05 ...

APOGEPHA Arzneimittel GmbH SWOT Analysis, Strategy, Revenues and Profits

APOGEPHA Arzneimittel GmbH SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Bladder, bladder weakness, urolithiasis, enuresis in children, prostate cancer, prostate enlargement, prostate syndrome, and bladder cancer among others. The company offers both prescription and non ...

PhytoMedical Technologies, Inc. (Symbol:PYTO) SWOT Analysis, Strategy, Revenues and Profits

PhytoMedical Technologies, Inc. (Symbol:PYTO) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Cancer(prostate, lung, brain and bladder cancer) and diabetes (including glucose, insulin, cholesterol, triglycerides and related variables). The company operates through its wholly owned subsidiaries ...

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2014, Global Markets Direct

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2014, Global Markets Direct

  • $ 2 000
  • Industry report
  • September 2014
  • by Global Markets Direct

... Therapeutic landscape of non muscle invasive bladder cancer (nmibc) (superficial bladder cancer)- the report reviews key pipeline products under drug profile section which includes, product description, mo ...

Oryzon Genomics S.A. - Product Pipeline Analysis, 2014 Update

Oryzon Genomics S.A. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • September 2014
  • by Global Data

... S diagnostic products include gynec-dx for endometrial cancer; cxbladder for bladder cancer; and colobraf for colorectal cancer. The company produces nces and monoclonal antibodies for neurogeneration and cancer ...

Mitomics Inc. - Product Pipeline Analysis, 2014 Update

Mitomics Inc. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • September 2014
  • by Global Data

... Diagnostic assay - bladder cancer - product status 13diagnostic assay - bladder cancer - product description 13diagnostic assay - lung cancer - product status 14diagnostic assay - lung cancer ...

About 500 reports for Bladder Cancer

Download Unlimited Documents from Trusted Public Sources

Pathology Description in Sweden

  • Urinary Bladder Cancer in Wegener's Granulomatosis: Risks and Re...
  • September 2014
    6 pages
  • Bladder Cancer  

    Cancer  

  • Sweden  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.